BRCA1 and cancer: PARP inhibitors provide a promising avenue of treatment for cancers associated with BRCA1/2 mutations.[8] The phase III randomized POLO trial (NCT02184195), in which the effectiveness of maintenance Olaparib monotherapy following cisplatin, carboplatin, or oxaliplatin is being assessed, is currently in process.